Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



A Study of ME-401 in Subjects With CLL / SLL, FL, and B-cell Non-Hodgkin's Lymphoma

Multiple Cancer Types

A Three-Arm Study of ME-401 in Subjects with Relapsed / Refractory CLL / SLL or FL, of ME-401 in Combination with Rituximab in Subjects with Relapsed / Refractory CLL / SLL or B-cell NHL, and of ME-401 in Combination with Zanubrutinib in Subjects with Relapsed / Refractory CLL / SLL or B-cell NHL
Leukemia, Lymphoma
I
Reddy, Nishitha
NCT02914938
VICCHEM1714

Study of ME-401 in Subjects With Follicular Lymphoma After Failure of Two or More Prior Systemic Therapies

This is the study of the PI3K? inhibitor ME-401 in subjects with relapsed / refractory follicular lymphoma after failure of at least 2 prior lines of systemic therapy
Not Available
II
Reddy, Nishitha
NCT03768505
VICCPCL1913

Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed / Refractory T-cell Lymphoma

To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) of Tenalisib in combination with Romidepsin in patients with R / R T-cell lymphoma.
Not Available
I/II
Reddy, Nishitha
NCT03770000
VICCPCL1937

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: